Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Allogene Therapeutics
Massachusetts General Hospital
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
St. Jude Children's Research Hospital
Malaghan Institute of Medical Research
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Medical University of South Carolina
Lyell Immunopharma, Inc.
National Institutes of Health Clinical Center (CC)
Essen Biotech
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Ohio State University Comprehensive Cancer Center
AIDS Malignancy Consortium
SWOG Cancer Research Network
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Ohio State University Comprehensive Cancer Center
St. Jude Children's Research Hospital
City of Hope Medical Center
City of Hope Medical Center
Case Comprehensive Cancer Center
Thomas Jefferson University
Northside Hospital, Inc.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
University of Rochester
UNC Lineberger Comprehensive Cancer Center
Acepodia Biotech, Inc.
Masonic Cancer Center, University of Minnesota
TriArm Therapeutics (Taiwan) Limited
University Health Network, Toronto
Mayo Clinic
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Chinese PLA General Hospital
Chinese PLA General Hospital
Case Comprehensive Cancer Center
Indapta Therapeutics, INC.
National University of Malaysia